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Abstract: Aromatase inhibitors (AIs) are becoming more widely used than tamoxifen as 
adjuvant hormonal therapy for postmenopausal women (PMW) with early breast cancer (EBC). 
It is clear that these drugs offer important efficacy benefits over tamoxifen and differ from 
tamoxifen in their safety profile. The accepted strategies for adjuvant AI therapy include initial 
adjuvant treatment following surgery, switching and/or sequencing from prior tamoxifen, and 
extended adjuvant therapy following the full 5 years of tamoxifen treatment. Among the avail-
able AIs, letrozole has been evaluated in large, well-controlled, double-blind clinical trials in the 
initial adjuvant, extended adjuvant, and more recently, the sequential adjuvant settings. Letrozole 
is the most potent of the AIs and provides near complete suppression of plasma estrogens in 
PMW. Letrozole also significantly reduces the occurrence of early distant metastases, the most 
lethal type of recurrence event, which can lead to improved survival. Clinical comparisons 
of letrozole with both tamoxifen and placebo have also provided important long-term safety 
data on the use of AIs as adjuvant therapy in PMW with EBC. The weight of clinical evidence 
indicates that letrozole is a safe and effective option for adjuvant hormonal therapy across all 
three AI treatment settings.
Keywords: aromatase inhibitor, breast cancer, hormonal therapy, letrozole, postmenopausal 
women, tamoxifen
Introduction
While adjuvant hormonal therapy continues to be the standard of care for 
postmenopausal women (PMW) with early breast cancer (EBC), there has been a 
shift in the treatment paradigm away from the more traditional 5 years of adjuvant 
tamoxifen to strategies employing the third-generation aromatase inhibitors (AIs) 
letrozole, anastrozole, and exemestane. A recent study found a marked increase in the 
use of AIs between the years 2000 and 2003, while the use of tamoxifen declined over 
the same time (Figure 1).1 In clinical trials, AIs have proven superior to tamoxifen in 
reducing breast cancer recurrence, although the treatment strategies examined have 
not been uniform across trials. While the Breast International Group (BIG) 1-982–5 and 
the Arimidex Tamoxifen Alone or in Combination (ATAC)6,7 trials have proven the 
superiority of the nonsteroidal AIs (letrozole or anastrozole, respectively) as initial 
adjuvant therapy compared with 5 years of tamoxifen, the Intergroup Exemestane Study 
(IES) has shown the superiority of switching to the steroidal AI exemestane following 
2 to 3 years of prior tamoxifen, in comparison with continuing tamoxifen.8,9 Other 
trials, including the Arimidex Nolvadex (ARNO) 95 study and the Italian Tamoxifen 
Arimidex (ITA) trial have examined a similar switch strategy using anastrozole.10,11 Therapeutics and Clinical Risk Management 2009:5 726
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BIG 1-98 also allowed for an analysis of sequential adjuvant 
therapy with letrozole before or after tamoxifen compared 
with letrozole monotherapy.2,5 The MA.17 trial has also 
examined the efficacy and safety of letrozole following 
the standard 5 years of adjuvant tamoxifen, in comparison 
with placebo (extended adjuvant therapy).12,13 The AIs have 
important safety benefits relative to tamoxifen. Whereas the 
adverse event (AE) profile associated with AI treatment is 
largely predictable in women undergoing extreme estrogen 
deprivation, sporadic and/or unforeseen serious complica-
tions such as stroke, thromboembolism, and endometrial 
cancer can occur with tamoxifen.14,15 Although the findings 
of the major AI trials support the use of AIs in these different 
treatment settings, the weight of clinical evidence strongly 
supports the initial use of AIs, while a switch to an AI after 
tamoxifen is an option for patients who do not begin their 
adjuvant treatment with an AI.
Letrozole is somewhat unique in that it has been evaluated 
in large, randomized, well-controlled trials across all three 
of the treatment paradigms (ie, initial adjuvant, sequential 
adjuvant, and extended adjuvant). As BIG 1-98 was initiated 
at a later time than trials such as ATAC or IES, knowledge 
of the overall AI side-effect profile also allowed for a more 
thorough assessment of its safety. Letrozole is effective in 
suppressing plasma estrogen levels to near-undetectable 
levels in PMW with EBC.16–18 Initial adjuvant letrozole has 
also proven significantly more effective than tamoxifen in 
reducing early distant metastases (DM),2,19 and this finding 
may be especially pertinent given the natural history of breast 
cancer. DM are known to be the most lethal of all recurrence 
events,20 and recent data demonstrate there is an early peak 
of recurrence at 2 years, most of which are DM recurrences, 
in patients receiving tamoxifen.21 It is therefore likely that 
treatments that reduce DM will eventually prolong overall 
survival (OS), and recent results with letrozole are supportive 
of this contention.3,5 In this review, we examine the efficacy 
and safety profile of letrozole when used as adjuvant therapy 
in PMW with EBC. Available efficacy and safety data from 
both published and abstract sources regarding the use of 
letrozole in the initial adjuvant, sequential adjuvant, and 
extended adjuvant settings were reviewed, as were studies 
with other AIs, where relevant, for comparative purposes.
Efficacy of letrozole
initial adjuvant therapy
BIG 1-98 was a uniquely designed trial initially developed 
to evaluate the impact of 5 years of letrozole or tamoxifen 
as initial adjuvant therapy in PMW with hormone receptor-
positive (HR+) EBC; it was later amended to include two 
sequential treatment arms, with letrozole or tamoxifen for 
the first 2 years, followed by the other drug for the remaining 
3 years of adjuvant treatment.2 The rigorous trial design also 
Figure 1 Dispensing of aromatase inhibitors within 2 years of diagnosis among women 55 years old (N = 13,245) diagnosed with hormone receptor-positive breast cancer, 
enrolled at 7 integrated health care delivery systems in the Cancer Research Network, for calendar years 2000–2003.  Drawn from data of Hortobagyi et al 2004.26
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provided for a large central assessment of receptor status, 
comprehensive safety assessment using Common Toxicity 
Criteria (CTC) 2.0 criteria, and lifelong monitoring of car-
diovascular events; the International Breast Cancer Study 
Group (IBCSG), an independent academic research group, 
conducted the trial. The primary core analysis (PCA) com-
pared initial therapy with letrozole and tamoxifen, including 
patients randomly assigned to sequential treatment, with all 
events censored after 30 days following treatment switch 
(N = 8,010). Later analyses at 5 and 10 years after initiation 
were planned for women assigned to the monotherapy arms 
(letrozole or tamoxifen for 5 years).2 The initial analysis, at 
a median 25.8-month follow-up, reported a significant 19% 
improvement in disease-free survival (DFS), the primary 
end point, a significant 28% improvement in time to recur-
rence, and a significant 27% improvement in time to distant 
recurrence (TTDR), as well as a trend toward improved OS 
compared with patients on tamoxifen (Table 1). Prospec-
tively-planned subgroup analysis also showed letrozole to be 
significantly more effective than tamoxifen across important 
patient groups, such as those with node-positive (N+) disease 
(hazard ratio [HR] 0.71; P  0.001), and those with large 
primary tumors (HR 0.76; P = 0.004).2
Following the reporting of these pivotal results, 
particularly in view of the significant DFS advantage and DM 
reductions with letrozole, the Data Safety Monitoring Board 
recommended that the IBCSG unblind the tamoxifen arm for 
ethical reasons. The IBCSG decided to counsel patients in 
the tamoxifen arm regarding letrozole’s superiority, and allow 
them to electively cross over to letrozole, while leaving the 
remaining arms blinded.3,5 Subsequent analyses are therefore 
impacted by the crossover of 619 patients (25.2%) from the 
tamoxifen arm. Notably, most patients who crossed over did so 
during years 3 to 5 and were generally high-risk patients, more 
likely to have N+ disease and larger tumors, vs those electing 
not to cross over.3,5 Despite the crossover in the intent-to-treat 
(ITT) population, long-term follow-up (median, 76 months) 
of the monotherapy population (N = 4,922) showed a 12% 
improvement in DFS, a 15% improvement in TTDR, and a 
13% improvement in OS that is approaching significance with 
letrozole relative to placebo in the ITT population (Table 1).5 
Because of the crossover, the true benefit of letrozole therapy 
is likely not reflected in the ITT analysis. An additional 
analysis has been reported that censors patients enrolled into 
the tamoxifen arm who elected to receive letrozole at the 
time of crossover, in an attempt to correct for the dilution of 
the letrozole effect. The censored analysis showed an even 
greater and significant superiority of letrozole on all end 
points, including OS, with a 16% improvement in DFS, a 
19% improvement in TTDR, and a 19% improvement in OS 
(Table 1).5 Although both the ITT and censored results are 
subject to potential biases, in favor of tamoxifen or letrozole, 
the true letrozole benefit over tamoxifen likely lies between 
the two. Recently reported findings at a median 60.5-month 
follow-up of the PCA population (N = 8,010) have corrobo-
rated these findings in both the ITT and censored analyses.3 
These results support the hypothesis that the early profound 
reduction in DM with letrozole leads to a survival benefit 
with longer follow-up.
The findings of BIG 1-98 demonstrate the superiority 
of letrozole over tamoxifen as initial adjuvant therapy in 
reducing recurrences overall, as well as DM recurrences, and 
the end point of OS has consistently trended better. Recent 
evidence indicates that DM are the most common type of 
Table 1 Efficacy end points from the Breast International Group (BIG) 1-98 and MA.17 trials: hazard ratios (HR) and (P value) for 
disease-free survival (DFS), time to recurrence (TTR), time to distant recurrence (TTDR), distant disease-free survival (DDFS), and 
overall survival (OS)2,5,13
BIG 1-98 MA.17
Letrozole vs tamoxifen Letrozole vs placebo
Follow-up 25.8 mo 76.0 moa 30.0 mo
N 8,010 4,922 5,187
DFS (P value) 0.81 (0.003) 0.88 (0.03) 0.84CeN (0.74–0.95) 0.58 (0.001)
TTR (P value) 0.72 (0.001) NR NR
TTDR (P value) 0.73 (0.001) 0.85 (0.05) 0.81CeN (0.68–0.96) NR
DDFS (P value) NR NR 0.60 (0.002)
OS (P value) 0.86 (0.16) 0.87 (0.08) 0.81CeN (0.69–0.94) 0.82 (0.3)
aHR for the intent-to-treat (iTT) analysis of the monotherapy arms at 76 months (P value) is shown; the HR (HRCeN) for the censored analysis (with 95% confidence interval) 
is shown below the iTT value.
Abbreviation: NR, not reported.Therapeutics and Clinical Risk Management 2009:5 728
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early recurrence event (occurring within 2 years of surgery) 
in patients on tamoxifen,21 and the benefit of letrozole on DM 
may be especially relevant, as distant recurrences have been 
associated with reduced OS and death from breast cancer 
compared with local recurrences.20 A prospectively planned 
retrospective analysis of BIG 1-98, which focused on early 
recurrence events (at 2 years), reported DM recurrences to be 
the predominant recurrence event at this time point, account-
ing for 74% of all recurrences.19 Letrozole significantly 
reduced early recurrence risk by 31% over tamoxifen in this 
analysis (117 events vs 168 events, HR 0.69; P = 0.002), with 
a 30% absolute reduction in DM events (87 vs 125 events, 
2.3% vs 3.3%) (Figure 2).19 Retrospective analysis from 
the similarly designed ATAC trial showed only a 7% reduc-
tion in early (2.5 years) DM events with anastrozole over 
tamoxifen.22 Notably, a significant effect of anastrozole on 
DM recurrences among the HR+ patients (N = 5,216) was 
not observed until after treatment completion, at a median 
follow-up of 100 months; no improvement in OS has emerged 
in the ATAC trial, and 5 fewer overall deaths were seen with 
anastrozole treatment relative to tamoxifen (all cause deaths, 
472 vs 477; HR 0.97; P = 0.7).7 In contrast, at 76 months 
in BIG 1-98 (N = 4,922), there were 40 fewer deaths with 
letrozole (overall deaths 303 vs 343), and this difference was 
due to the avoidance of cancer death events, as the number 
of deaths without a prior cancer event was equal in the two 
arms (87 and 87 events).5 The findings of BIG 1-98 over 
time show the importance of reducing early DM events and 
support the contention that significant reductions in early DM 
will lead to long-term improvements in OS.23
Letrozole vs anastrozole – FACE
The difference in outcome between ATAC and BIG 1-98, 
as noted above, is illustrative of the impact of early DM 
reduction on survival and also suggests a potential difference 
in efficacy between these two nonsteroidal AIs. Indeed, 
there is evidence for a greater suppression of both plasma 
and tissue estrogen levels with letrozole compared with 
anastrozole treatment (Figure 3).16–18 While ATAC and BIG 
1-98 are not directly comparable because of differences in 
design and follow-up, a recently completed trial, the Femara 
Anastrozole Clinical Evaluation (FACE), has compared 
the efficacy and safety of initial adjuvant treatment with 
these agents in a head-to-head fashion in a population of 
PMW with HR+, N+, EBC.24,25 The forthcoming results of 
this trial, once available, should provide, for the first time, 
a directly comparative assessment of both efficacy and safety 
for these two AIs in the important high-risk population of 
N+ EBC patients.
Sequential adjuvant therapy – BIG 1-98
The sequential arms of BIG 1-98 were designed to evaluate 
the efficacy and safety of letrozole and tamoxifen used in 
sequence with either agent for the first 2 years followed by 
the other for the remaining 3 years (letrozole  tamoxifen 
or tamoxifen  letrozole). Although other trials (eg, IES, 
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Figure 2 Reduction in overall, local, contralateral, and distant metastatic recurrences with letrozole over tamoxifen at early (2 years) follow-up in the Breast International 
Group 1-98 trial. The corresponding reductions in each type of recurrence are 30.4%, 47.8%, 26.7%, and 30.4%, respectively. Drawn from data of Mauriac et al 2007.19Therapeutics and Clinical Risk Management 2009:5 729
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ARNO 95, and ITA) have examined switching to an 
AI (exemestane or anastrozole) after 2 to 3 years of prior 
tamoxifen in relation to continued tamoxifen, only patients 
remaining recurrence-free after the tamoxifen treatment were 
randomized, and events were considered only from the time 
of the switch onward.8,10,11 The sequential therapy analysis 
of BIG 1-98, by comparison, considered all events from the 
time of randomization onward, allowing for a more accurate 
assessment of sequential treatment.5 Although the trial was 
not powered to compare efficacy of the sequential arms with 
letrozole monotherapy, this was believed to be the most 
relevant comparison, given the already proven superiority 
of letrozole over tamoxifen. In addition, comparisons with 
the tamoxifen monotherapy arms would not be interpretable 
because of the aforementioned crossover of patients from 
this arm to letrozole. The results of pairwise comparisons of 
the sequential arms with the letrozole monotherapy arm at a 
median follow-up of 71 months have been recently reported.5 
As these comparisons were not a primary analysis, 2-sided 
99% confidence intervals (CIs) were presented, and as a 
Figure 3 (A) Comparison of residual estrogen fractions in plasma following 6 weeks’ treatment with letrozole or anastrozole. The difference in suppression was significant 
for each fraction (for estradiol, P = 0.018; for estrone, P = 0.003; for estrone sulfate, P = 0.003).16 (B) Comparison of residual estrogen fractions in tumor tissue following 
16 weeks’ neoadjuvant treatment with letrozole or anastrozole (P values not reported).  Drawn from data of Geisler et al 2008.16
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superiority trial, the lack of significance cannot be inferred 
as equivalence between the treatments. Overall results did 
not show a significant benefit of either sequential approach 
in terms of DFS, TTDR, or OS (Table 2). Importantly, the 
risk of DM was consistently less with letrozole monotherapy 
compared with either sequential approach (Table 2).5 These 
initial findings support the importance of initiating with 
letrozole after surgery and maintaining letrozole therapy for 
5 years to provide maximal benefit.
extended adjuvant therapy – MA.17
Given the established superiority of AIs over tamoxifen, it is 
evident that AI therapy should be a component of adjuvant 
hormonal therapy, and this is not limited to the first 5 years 
after surgery; indeed, recurrence risk can extend beyond 
5 years, even among relatively low-risk, N– patients.26 Results 
from the MA.17 trial have shown that adjuvant AI therapy 
with letrozole can be offered to those women who have 
already received 5 years of tamoxifen. This trial randomized 
patients with 4.5 to 6.0 years of prior adjuvant tamoxifen to 
further therapy with letrozole or placebo.12 Initial findings 
of this trial showed a significant, 43% reduction in recur-
rences by 2.4 years of follow-up, and this important finding 
resulted in a decision to unblind the trial and allow women 
on placebo the opportunity to cross over to letrozole.12 
At a median 30-month follow-up, there was a significant 
42% reduction in recurrence, a 37% reduction in contralateral 
breast cancers (HR 0.63; P = 0.12), and a significant 40% 
reduction in distant recurrence with letrozole over placebo 
(Table 1).13 While the observed 18% improvement in OS 
with letrozole over placebo was not significant in the overall 
population (Table 1), subgroup analysis showed a significant, 
39% improvement in OS with letrozole in the N+ subgroup 
(N = 2,360; HR 0.61; P = 0.04).13 A subsequent modeling 
study from MA.17 found a significant benefit of letrozole 
therapy with longer treatment, such that the longer patients 
were exposed to letrozole, the greater the benefit.27 In the 
overall population, the improvement in DFS (6 months: 
HR 0.59, 48 months: HR 0.19; P  0.0001) and distant 
disease-free survival (DDFS; 6 months: HR 0.51, 48 months: 
HR 0.21; P = 0.0013) both significantly increased over time, 
whereas the improvement in OS remained similar (6 months: 
HR 0.87, 48 months: HR 0.79; P = 0.33).27 This suggests 
that, while the MA.17 trial was unblinded at a median of 
30 months, the benefit of letrozole in DFS and DDFS extends 
well beyond this, up to 48 months.
Further analysis of MA.17 has examined outcomes in 
women who elected to cross over to letrozole following 
unblinding. A total of 1,579 of 2,383 patients (66%) origi-
nally assigned to placebo elected to cross over to letrozole 
after unblinding. At a median of 64 months’ follow-up, 
patients who received letrozole continued to show a sig-
nificant 32% improvement in DFS (HR 0.68; P = 0.0001) 
and a 20% improvement in DDFS (HR 0.80; P = 0.082), 
despite the crossover of these patients.28 Finally, another 
study has compared outcomes in patients who crossed over 
from placebo to letrozole (placebo  letrozole; N = 1,579) 
with those who elected to remain on placebo following 
unblinding of the trial (placebo  placebo; N = 804), allow-
ing for an assessment of the efficacy of extended adjuvant 
letrozole in patients who had been off tamoxifen therapy 
for a median of 2.8 years (range, 1.1 to 7.1 years).29 The 
results of this analysis showed significant improvements 
in DFS (63%; HR 0.37; P  0.0001), DDFS (61%; HR 
0.39; P = 0.004), and OS (70%; HR 0.30; P  0.0001) 
for patients in the placebo  letrozole compared with the 
placebo  placebo group, suggesting a benefit of extended 
adjuvant letrozole over placebo, even for patients who had 
been off tamoxifen as long as 7 years.29 The results of MA.17 
demonstrate the efficacy of extended adjuvant letrozole and 
allow an important treatment option for patients that can 
provide longer protection against the risk of breast cancer 
recurrence.
Safety profile of letrozole
As adjuvant hormonal therapy is indicated for all women 
with HR + EBC, the assessment of AI safety has been, 
unfortunately, confounded by comparisons with treatment 
groups receiving tamoxifen, which can have beneficial effects 
on lipids, bone, and cardiovascular outcomes in PMW.14,30–34 
Tamoxifen can also influence safety outcomes by virtue of 
its own AE profile, which includes an increased risk for 
endometrial abnormalities and/or cancers, thromboembolic 
events, and stroke.14,15 As AI therapy is associated with 
Table 2 Efficacy end points (hazard radio [HR] and 99% confidence 
interval [CI]) from the sequential therapy analysis of the Breast 
International Group (BIG) 1-98 trial (pairwise comparisons with 
letrozole [LET] monotherapy) at a median 71-month follow-up
End point TAMLET vs LET LETTAM vs LET
HR 99% CI HR 99% CI
DFS 1.05 0.84–1.32 0.96 0.76–1.21
OS 1.13 0.83–1.53 0.90 0.65–1.24
TTDR 1.22 0.88–1.69 1.05 0.75–1.47
Drawn from data of Mouridsen 2009.5
Abbreviations: DFS, disease-free survival;  OS, overall survival;   TAM, tamoxifen, 
TTDR, time to distant recurrence.Therapeutics and Clinical Risk Management 2009:5 731
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profound suppression of plasma estrogens, safety findings 
from the major AI trials have shown increases in osteoporosis 
and/or fracture risk, as well as musculoskeletal symptoms 
such as arthralgias and myalgias (commonly observed during 
menopause) in women receiving adjuvant AI therapy relative 
to tamoxifen.2,3,6,8,9 Unlike other AIs, the toxicity profile of 
letrozole has been studied in double-blind studies not only in 
relation to tamoxifen (BIG 1-98) but also in relation to pla-
cebo (MA.17). This allows for a more complete assessment 
of safety issues in populations receiving adjuvant tamoxifen, 
as well as those who have completed their tamoxifen treat-
ment. In particular, BIG 1-98, as noted earlier, allowed for 
a very comprehensive assessment of cardiovascular safety, 
and the effect of letrozole on lipids and bone health also has 
been well studied. Other symptoms associated with estrogen 
suppression, such as joint and/or musculoskeletal symptoms, 
hot flashes,35 gynecological effects, and changes in mood 
and/or cognition, are a source of concern for many patients 
on AIs or tamoxifen,36 and available data regarding the impact 
of letrozole on these parameters is also reviewed below.
Cardiovascular health
There has been much improvement in the treatment of 
EBC, and with the current standard of care, breast cancer 
has become more of a chronic condition, meaning most 
patients will live for an extended period with their disease 
while remaining at risk for disease recurrence. Considering 
the mean age of patients enrolled in many AI trials is about 
60 to 65 years,2,8,10,13 other competing causes of death, such 
as cardiovascular disease, will become evident, and this 
needs to be considered in the overall outcome of clinical 
trials. BIG 1-98, as already noted, allowed for the prospective 
collection and grading of AEs using CTC 2.0 criteria, and 
lifelong assessment of cardiovascular outcomes, and this 
enables a very thorough assessment of the impact of these 
competing causes of death on outcome.
Letrozole vs tamoxifen
At 25.8 months’ median follow-up, BIG 1-98 reported 
a higher incidence of hypercholesterolemia for patients 
assigned to letrozole vs those assigned to tamoxifen (Table 3), 
but this likely reflected a cholesterol-lowering effect of 
tamoxifen; cholesterol levels remained unchanged with 
letrozole, decreasing by only –1.8% at 24 months, whereas 
the reduction was –14.1% by 24 months in tamoxifen-treated 
patients.2 Hypercholesterolemia was reported at least once 
in more letrozole-treated vs tamoxifen-treated patients 
(Table 3), and most events were grade 1 (35.1% and 17.3%, 
respectively). Cholesterol assessments were prospectively 
collected every 6 months, and most were non-fasting. 
A single incident of elevated serum cholesterol was counted 
as an AE regardless of whether or not subsequent levels 
were normal, and as such, hypercholesterolemia events 
in BIG 1-98 cannot be considered a medical diagnosis. 
At 60.5 months, there was again more (∼2-fold), mostly 
grade 1, hypercholesterolemia with letrozole,3 and thus, the 
results with regard to this AE have been consistent, with no 
evidence for an increasing risk for hypercholesterolemia with 
Table 3 Cardiovascular safety: percent of patients with indicated event (P value) for patients in the letrozole (LET) versus tamoxifen 
(TAM) (Breast International Group [BIG] 1-98) and LET versus placebo (PBO) groups (MA.17), respectively2,13
BIG 1-98 MA.17
LET vs TAM LET vs PBO
Follow-up 25.8 mo 60.5 mo 30.0 mo
N 8,010 7,963 5,149
Hypertension NR NR 5.0 vs 5.0 (0.94)
Hypercholesterolemia 43.6 vs 19.2 (NR) 48.7 vs 24.1 (NR) 16.0 vs 16.0 (0.79)
CvA/TiA 1.0 vs 1.0 (0.91) 1.4 vs 1.5 (NR) 0.7 vs 0.6 (NR)
Thromboembolic event 1.5 vs 3.5 (0.001) 2.0 vs 4.1 (NR) 0.4 vs 0.2 (NR)
Cardiovascular disease NR NR 5.8 vs 5.6 (0.76)
Cardiac event 4.1 vs 3.8 (0.61) 5.6 vs 5.4 (NR) NR
ischemic heart disease 1.4 vs 1.2 (0.28) 2.1 vs 1.7 (NR) NR
Cardiac failure 0.8 vs 0.4 (0.01) 1.0 vs 0.8 (NR) NR
Other Cv event 0.5 vs 0.2 (0.04) 0.9 vs 0.5 (NR) NR
Grade 3–5 CV event 3.7 vs 4.2 (P = NS) NR NR
Grade 3–5 cardiac event 2.1 vs 1.1 (0.001) 2.8 vs 1.7 (NR) NR
Abbreviations: CVA/TIA, cerebrovascular accident/transient ischemic attack; NS, not significant; NR, not reported.Therapeutics and Clinical Risk Management 2009:5 732
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letrozole over time (ie, 2.3-fold at 25.8 months vs 2.0-fold 
at 60.5 months). In addition, if hypercholesterolemia were 
truly an effect of letrozole therapy, an increased overall 
cardiovascular risk would be expected over time, and, as 
detailed further below, this is not supported by long-term 
cardiovascular outcome data in BIG 1-98. The safety results 
of BIG 1-98 at 25.8 months and at 60.5 months showed a 
rare but higher incidence of grade 3–5 cardiac events with 
letrozole. However, over time, the cardiac safety findings are 
consistent, with no evidence of increasing risk for grade 3 
to 5 cardiac events (Table 3) with letrozole in the large PCA 
population (N = 8,010) of patients (ie, 1.9-fold higher at 25.8 
months, 1.6-fold higher at 60.5 months).
Very similar findings were reported in a detailed safety 
analysis from BIG 1-98 (N = 7,963) at a median 30.1-month 
follow-up. Total cholesterol decreased over time in both 
groups, but reduction was more pronounced in the tamoxifen 
group, while a decrease with letrozole was apparent after 
30 months.37 More patients receiving letrozole had an increase 
from baseline in their total cholesterol at each follow-up 
visit, which explains the higher proportion of low-grade 
hypercholesterolemia,37 although in this analysis, almost all 
(91%) of the measurements were non-fasting. Significantly 
more grade 3-5 cardiac events (2.4% vs 1.4%; P = 0.001), 
specifically grade 3 to 5 cardiac failure (0.7% vs 0.3%; 
P = 0.04), were seen with letrozole, while significantly 
more grade 3 to 5 thromboembolic events (0.9% vs 2.3%; 
P  0.001) were seen with tamoxifen.37 This analysis also 
found that a prior cholesterol elevation was associated with 
reporting of a grade 3 to 5 cardiac AE, but the association could 
not completely explain the increase in events with letrozole. 
Notably, the incidence (overall, grades 1 to 5) of ischemic 
heart disease (1.7% vs 1.5%; P = 0.48), cerebrovascular 
events (1.2% vs 1.2%; P = 0.92), and hypertension (3.8% vs 
3.4%; P = 0.37) did not differ between the groups.37
Although also reportedly consistent with earlier results, 
updated, detailed safety findings from the monotherapy 
patients (N = 4,922) at 76 months are not yet available. 
However, the number of deaths without a cancer event was 
identical with both letrozole and tamoxifen in this analysis,5 
which argues against any significant adverse impact of 
letrozole on cardiac outcomes.
Letrozole vs placebo – MA.17
As tamoxifen is known to have beneficial effects on lipids and 
cardiac health, the comparison of letrozole with placebo in 
MA.17 allows for a more accurate assessment of the effects of 
letrozole on lipids and cardiovascular outcomes in a population 
of PMW who have all received prior tamoxifen.12 Analysis of 
safety in MA.17 did not show a significant difference in the 
incidence of hypercholesterolemia or cardiovascular dis-
ease between the letrozole and placebo treatment groups 
(Table 3).12,13 A companion lipid substudy of MA.17 has further 
examined lipid profiles over time (6, 12, 24, and 36 months) 
in letrozole- and placebo-treated patients (N = 347). The 
overall conclusions of the study suggested no significant 
adverse impact of letrozole on serum cholesterol, high-density 
lipoprotein (HDL), low-density lipoprotein (LDL), or triglyc-
erides in women without hyperlipidemia at baseline.38 The 
only significant differences in the percentage change from 
baseline between treatment groups were in HDL at 6 months 
(P = 0.049), LDL at 12 months (P = 0.033), and triglycerides 
at 24 months (P = 0.036).38 There was no significant differ-
ence between treatment groups in the percentage of patients 
exceeding predefined thresholds for lipid parameters.38
Letrozole vs other AIs
The ATAC and BIG 1-98 trials differed in their collection 
of AEs, so cardiovascular safety results are not directly 
comparable. Nonetheless, increases in cholesterol and some 
cardiac outcomes are seen in patients with all AIs compared 
with tamoxifen.6,9,39 A recently reported comparative study 
of the lipid effects of letrozole and anastrozole suggests 
similar effects by these two nonsteroidal AIs on lipid param-
eters in PMW.40 In an open-label pharmacokinetic study 
(Anastrozole vs Letrozole, an Investigation of QUality Of 
life and Tolerability [ALIQUOT]), patients (N = 57) were 
randomized to 12 weeks of letrozole followed by 12 weeks 
of anastrozole or the reverse sequence. There were no major 
differences between the drugs except for an increase in LDL 
cholesterol with letrozole at 6 months (P = 0.04) compared 
with anastrozole. Notably, in patients recently completing 
tamoxifen therapy, both drugs caused beneficial changes in 
lipid parameters (lower triglycerides) compared with those 
not having a prior tamoxifen exposure.40
Summary – cardiovascular effects
The overall results of BIG 1-98 and MA.17 do not suggest 
a significant adverse impact of letrozole therapy on 
hypercholesterolemia or cardiovascular outcomes. However, 
care should always be taken to monitor and appropriately 
treat patients with preexistent cardiovascular risk factors 
and/or hypercholesterolemia while undergoing therapy with 
letrozole or any AI. Although the number of events was rare, 
the increase in grade 3 to 5 cardiac AEs over tamoxifen in 
BIG 1-98 can only be partly explained by prior cholesterol Therapeutics and Clinical Risk Management 2009:5 733
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elevation, and it has been suggested that the small increase 
in incidence was due to a vascular endothelial effect arising 
from the profound estrogen suppression by letrozole.37 The 
lack of such an effect in MA.17 suggests it is more likely 
due to the beneficial effect of tamoxifen on cardiac health.37 
It should be noted as well that, despite any potential impact 
of either therapy on these outcomes in BIG 1-98, OS favors 
letrozole over the long term. In particular, as noted earlier, 
the number of deaths caused by a non-cancer event was 
identical in the monotherapy follow-up at 76 months,5 and 
similar findings were seen in the 60.5-month update of the 
PCA population.3 Long-term results from BIG 1-98 suggest 
no increase in the risk of cardiovascular events over time, 
despite the advance in age of women in BIG 1-98 from a 
median of 61 years at the start of the study2 to about 67+ years 
by the latest follow-ups.3,5
Bone health
Declining estrogen levels are known to have an effect on bone 
health during natural menopause, and it can be expected that 
a profound further suppression of estrogen during AI therapy 
(Figure 3) in PMW will predispose women to loss of bone 
mineral density (BMD) and an accompanying increase in 
fracture risk.
Letrozole vs tamoxifen – BIG 1-98
Safety findings of the PCA showed a significantly higher 
incidence of fracture (about 1.4-fold) with letrozole compared 
with tamoxifen, although these events were relatively infre-
quent, occurring in 6% of patients (Table 4). A similar 
significantly higher incidence (about 1.3-fold) was seen in the 
60.5-month PCA update, and again, the risk of fracture does 
not appear to be increasing over time (1.4-fold vs 1.3-fold).
Letrozole vs placebo – MA.17
An effect of tamoxifen on bone health in the safety analysis 
of BIG 1-98 cannot be excluded, and thus, the comparison of 
letrozole with placebo in MA.17 may be more informative. 
New-onset osteoporosis was reported by more women on 
letrozole compared with placebo in MA.17, and the difference 
reached significance by 30 months of follow-up (Table 4). 
Importantly, fractures were again relatively infrequent (6% 
overall), and while trending higher with letrozole, the difference 
was not significant compared with placebo (Table 4).
Letrozole vs other AIs
In a recent report from the ALIQUOT study, the impact of 
AI therapy with letrozole and anastrozole on bone turnover 
was compared.41 In this study, despite the above-noted 
greater suppression of estrogen with letrozole, both AIs had 
similar effects on bone, with an increase in bone turnover 
over time (6 months compared with 3 months). The findings 
of the study did not suggest any likely differential effect of 
either drug on fracture rate or the incidence of osteoporosis. 
Another important finding of the study was that both AIs 
caused significant increases in bone turnover when tamoxi-
fen was withdrawn and replaced by an AI, suggesting that 
prior tamoxifen use has a major impact on AI-related bone 
effects.41 This was corroborated in another study that also 
found similar effects on bone turnover markers with the 
nonsteroidal AIs anastrozole and letrozole and the steroidal 
AI exemestane.42
Treatment of bone loss – Z-FAST  
and ZO-FAST
While the loss of BMD and the associated increase in 
fracture risk is an important safety consideration for patients 
receiving AI therapy, the efficacy benefits of AIs over tamoxi-
fen in terms of reducing recurrences, especially DM, will 
likely outweigh this risk for a majority of patients. In addition, 
emerging evidence suggests that bisphosphonate therapy with 
zoledronic acid (ZA) can not only treat bone loss but also can 
effectively prevent AI-associated bone loss (AIBL). The effi-
cacy and safety of concomitant bisphosphonate therapy with 
ZA to prevent AIBL in patients receiving letrozole has been 
investigated in two similarly designed trials, Z-FAST (United 
States) and ZO-FAST (Europe) (Zometa Femara Adjuvant 
Synergy Trial).These trials randomized patients receiving 
adjuvant letrozole to either upfront ZA, initiated at random-
ization and every 6 months, or delayed ZA, initiated with a 
post-baseline decrease of −2.0 in the T-score at either the 
lumbar spine or the total hip, or in the event of a non-traumatic 
clinical fracture.43,44 The 12-month results from the Z-FAST 
trial (N = 602) showed that upfront ZA could effectively 
Table 4 Bone and musculoskeletal events: percent of patients with 
indicated event (P value) for patients in the letrozole (LET) versus 
tamoxifen (TAM) (Breast International Group [BIG] 1-98) and LET 
vs placebo (PBO) groups (MA.17), respectively2,3,13
BIG 1-98 MA.17
LET vs TAM LET vs PBO
Follow-up 25.8 mo 60.5 mo 30.0 mo
N 8,010 7,963 5,149
Osteoporosis NR NR 8.1 vs 6.0 (0.003)
Fracture 5.7 vs 4.0 (0.001) 7.5 vs 5.7 (NR) 5.3 vs 4.6 (0.25)
Abbreviation: NR, not reported.Therapeutics and Clinical Risk Management 2009:5 734
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prevent bone loss at both the lumbar spine and total hip. 
Whereas BMD decreased in the delayed group, it increased 
in the upfront group, and the mean percent difference in 
BMD between the treatment groups was 4.4% at the lumbar 
spine (P  0.0001) and 3.3% at the total hip (P  0.0001). 
Moreover, nearly 4-fold more patients with normal BMD 
(at the lumbar spine and/or total hip) at baseline developed 
mild/moderate osteopenia by 12 months in the delayed group 
compared with the immediate group (12.6% vs 3.4%). Simi-
larly, more patients with mild/moderate osteopenia at base-
line progressed to severe osteopenia/osteoporosis by month 
12 in the delayed group (14.8% vs 1.4%, respectively).43 The 
incidence of low/no trauma fractures (0.7% vs 1.0%), and the 
incidence of traumatic fractures (2% vs 2.3%), did not differ. 
At the 36-month follow-up, similar results were observed, 
with a difference at the lumbar spine of 6.7% (P  0.001) 
and at the total hip of 5.2% (P  0.001).45 The findings of 
Z-FAST thus demonstrate that AIBL in PMW with breast 
cancer receiving adjuvant letrozole can be effectively 
prevented with upfront ZA treatment, and bisphosphonate 
therapy represents an attractive option for patients who may 
be at risk for bone loss while on AIs. Recent results from the 
companion ZO-FAST study at 36 months are also suggestive 
of a further benefit of ZA therapy. In addition to preventing 
AIBL, as in Z-FAST, there was a significant improvement 
in DFS for patients receiving immediate ZA vs delayed ZA 
(HR 0.588; P = 0.0314).46 Reports of a beneficial effect of 
ZA treatment on disease recurrence in premenopausal women 
receiving hormonal therapy with goserelin and anastrozole 
in a different trial,47,48 and a similar emerging benefit in 
the Z-FAST trial,45 suggest that, in addition to its effective 
prevention of AIBL, upfront ZA therapy has an antitumor 
efficacy benefit as well.
Musculoskeletal symptoms
Musculoskeletal symptoms including arthralgia and myalgia 
are commonly seen during menopause and in women 
undergoing estrogen suppression. In BIG 1-98, the incidence 
of these events was higher with letrozole vs tamoxifen, but 
the difference was only significant in the case of arthralgia 
(Table 5). In MA.17, arthralgia and myalgia were observed 
in between 12% and 25% of the patients overall, and the 
incidence of both was significantly higher with letrozole rela-
tive to placebo (Table 5), which likely reflects the profound 
estrogen suppression in women on letrozole relative to 
placebo. Interestingly, recent data from the ATAC study have 
linked the emergence of joint symptoms such as arthralgia 
with the efficacy of AIs, such that patients displaying these 
symptoms have a lower risk for recurrence.49 Whether the 
same is true for letrozole will require further investigation, 
but these findings highlight the link between the estrogen-
suppressing activities of the AIs (as manifested by the occur-
rence of joint symptoms) and efficacy in terms of recurrence 
risk reduction. Evidence from recent studies also suggests 
that switching between AIs may be one way to alleviate joint 
symptoms in patients without losing the efficacy benefit of 
continued AI therapy. It had been reported previously that 
more than half of patients experiencing joint symptoms 
on one AI (letrozole or anastrozole) did not experience 
joint symptoms while on the other AI.50 Findings from the 
Articular Tolerance of Letrozole (ATOLL) study (N = 179) 
examined the effect of a switch to letrozole in patients on 
anastrozole with joint pain severe enough to require dis-
continuation. At the end of 6 months, most (71.5%) of the 
patients elected to remain on letrozole, while the remainder 
(28.5%) discontinued because of severe joint pain.51 These 
findings support a simple yet effective treatment option 
(ie, switching from one AI to the other) for most patients 
with troublesome joint symptoms who might otherwise need 
to discontinue AI therapy.
Cognitive function
With the increased use of AIs as adjuvant hormonal therapy 
and the markedly greater suppression of plasma estrogens 
associated with such therapy, the effects of AI treatment on 
cognition will be important to consider. Studies in animals 
suggest that estrogen receptors in the brain can have an 
impact on cognition and/or cognitive performance, and that 
estrogens can have an important neuroprotective effect.52–54 
Accordingly, the menopause-associated decline in estrogen 
level has been associated with declines in cognitive function, 
and conversely, some studies suggest that higher endogenous 
estrogens can prevent cognitive decline, although the data 
are not entirely consistent.52,55 Because cognitive decline can 
have a dramatic impact on quality of life (QOL) in long-term 
survivors of breast cancer, the potential impact of AI therapy 
needs further investigation.55
In a pilot study of 184 women enrolled in ATAC, the 
patient group receiving anastrozole or tamoxifen had signifi-
cantly impaired verbal memory (P = 0.026) and processing 
speed (P = 0.032) relative to a healthy control group.56,57 
It should be noted that the ATAC study compared women 
with breast cancer to healthy controls, which can present 
biases, as the diagnosis of breast cancer alone can impact 
cognition.58 The Cognition in the Study of Tamoxifen and 
Raloxifene (Co-STAR) will be interesting, as the trial is Therapeutics and Clinical Risk Management 2009:5 735
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designed to compare the cognitive effects of the two agents 
in the absence of disease.59 Another study (N = 31) comparing 
women receiving anastrozole and tamoxifen in ATAC found 
that women receiving anastrozole had significantly poorer 
performance on learning and memory measures than women 
receiving tamoxifen.60 Although preliminary, the data are 
suggestive of a role for estrogen in cognition and a potential 
impact of AI therapy on some measures of cognitive func-
tion, and this is an area that is certainly worthy of additional 
investigation. Analyses looking into the effect of letrozole 
compared with tamoxifen on cognitive function have been 
conducted for BIG 1-98 and are to be presented at the 2009 
American Society of Clinical Oncology meeting.
Other events
Menopausal symptoms such as hot flashes, and gynecologic 
events including vaginal discharge, bleeding, and/or dryness 
may also occur in a substantive proportion of women receiving 
adjuvant hormonal therapies with either AIs or tamoxifen, and 
these can be a source of distress and reduced QOL for women 
undergoing adjuvant therapy. One “patient-perspective” 
study reported hot flashes, weight gain, insomnia, and joint 
aches as most troublesome for patients on hormonal therapy, 
with all of these except joint aches occurring at approxi-
mately equivalent frequency in AI- and tamoxifen-treated 
patients.36 Other notable symptoms included loss of libido, 
vaginal dryness, vaginal discharge, muscle aches, and mood 
changes, all of which occurred at roughly similar frequencies 
in about 70% to 85% of the patients receiving tamoxifen or 
AIs. These findings illustrate the disparity between safety 
results from AI trials and “real life” situations and highlight 
the importance of addressing these concerns to assure patient 
compliance with hormonal therapy.
Letrozole vs tamoxifen – BIG 1-98
Results from BIG 1-98 (Table 5) comparing initial adjuvant 
letrozole with tamoxifen have shown a significantly lower 
incidence of vaginal bleeding with letrozole, as well as a 
lower incidence of vasomotor events such as hot flashes and 
night sweats. However, hot flashes still occurred in about 
one third of the patients in each group, as would be expected 
in a population of PMW undergoing hormonal treatment 
(Table 5). There was also less need for endometrial biopsy 
in patients taking letrozole vs tamoxifen (2.3% vs 9.1%; 
P  0.001) in the PCA, and the incidence of invasive endo-
metrial cancer, although quite rare (0.5%) in both groups, 
trended lower with letrozole (0.1% vs 0.3%; P = 0.18).2 
Long-term follow-up of the PCA population at 60.5 months 
of median follow-up has yielded very similar findings with 
respect to these events (Table 5).3
Letrozole vs placebo – MA.17
The population in MA.17 included women who had received 
tamoxifen for 4.5 to 6.0 years,12 and the incidence of vaso-
motor symptoms at the latest follow-up was high in this 
patient group, with 50% or more reporting hot flashes, and 
more patients in the letrozole group reporting this symptom 
(Table 5). Night sweats were also seen in about one third 
of the patients, but the incidence was similar between the 
treatment groups. The incidence of vaginal dryness also 
Table 5 Other adverse events: percent of patients with indicated event (p value) for patients in the letrozole (LET) versus tamoxifen 
(TAM) (Breast International Group [BIG] 1-98, Primary Core Analysis population) and LET versus placebo (PBO) groups (MA.17), 
respectively2,3,13
BIG 1-98 MA.17
LET vs TAM LET vs PBO
Follow-up 25.8 mo 60.5 mo 30.0 mo
N 8,010 7,963 5,149
Arthritis NR NR 6.0 vs 5.0 (0.07)
Arthralgia 20.3 vs 12.3 (0.001) 21.9 vs 16.5 (NR) 25.0 vs 21.0 (0.001)
Myalgia 6.4 vs 6.1 (0.61) 7.8 vs 7.4 (NR) 15.0 vs 12.0 (0.004)
Bone pain NR NR 5.0 vs 6.0 (0.67)
vaginal bleeding 3.3 vs 6.6 (0.001) 3.9 vs 8.0 (NR) 6.0 vs 8.0 (0.005)
vaginal dryness NR NR 6.0 vs 5.0 (0.26)
Hot flashes/flushes 33.5 vs 38.0 (0.001) 35.2 vs 39.5 (NR) 58.0 vs 54.0 (0.003)
Night sweats/sweating 13.9 vs 16.2 (0.004) 14.7 vs 16.9 (NR) 30.0 vs 29.0 (0.48)
Abbreviation: NR, not reported.Therapeutics and Clinical Risk Management 2009:5 736
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was not significantly different between the groups; however, 
vaginal bleeding was significantly higher in the placebo 
group (Table 5). Although rare (6%) in either group, 
other events that were significantly higher with letrozole vs 
placebo were alopecia (5% vs 3%; P = 0.01) and anorexia 
(6% vs 4%; P = 0.039).13
QOL considerations
Studies evaluating the impact of AIs on QOL outcomes have 
generally suggested no overall adverse impact of AI therapy. 
Physical and mental QOL measures such as the 36-item short 
form health survey (SF-36), the estrogen suppression-related 
scale (Menopause-Specific Quality of Life [MENQOL]), 
and others have been assessed in QOL studies from MA.17, 
ATAC, and the IES.61–64 In the MA.17 QOL study, patients 
were stratified by age group (65 years and 65 years), and 
no statistically significant differences (letrozole vs placebo) 
were seen in either age group in MENQOL psychosocial and 
physical domains or in the SF-36 mental QOL summary score, 
physical functioning, role-physical, general health, social 
functioning, role-emotional, and mental health subdomains.62 
By comparison, both age groups showed significant differences 
in favor of placebo for SF-36 bodily pain and MENQOL 
vasomotor symptoms. Significant differences in favor of letro-
zole were seen for the MENQOL sexual functioning domain 
in the younger group. Differences in the older group favored 
placebo in the SF-36 physical summary score and vitality at 
selected time points. Nevertheless, although significant, the 
differences were not considered clinically meaningful by 
current methods.62 Another assessment of QOL from MA.17 
showed no detrimental effect of extended adjuvant letrozole 
on overall QOL, despite small differences in QOL scores in 
selected domains such as physical function, bodily pain, vitality, 
vasomotor, and sexual. The findings were consistent with the 
letrozole toxicity profile in women with menopause related-
symptoms (eg, arthralgias, hot flashes), which could be a source 
of decreased QOL for some patients receiving letrozole.61
Conclusions
Both BIG 1-98 and MA.17 have provided pivotal data 
regarding the safety and efficacy of letrozole as adjuvant 
hormonal therapy in PMW with EBC. The efficacy results of 
MA.17 suggest that, for PMW who have not had the benefit 
of initial AI therapy during the first 5 years after surgery 
and have already completed tamoxifen therapy, extended 
adjuvant therapy with letrozole offers significant benefits 
over no additional treatment, even when letrozole is started 
as many as 7 years after completion.13,29 Notably, however, 
the efficacy results of the sequential therapy analysis from 
BIG 1-98 illustrate that there is no better treatment strategy 
than upfront letrozole.5 Indeed, the results from BIG 1-98 
have established the efficacy of initial adjuvant hormonal 
treatment with letrozole over tamoxifen for PMW with 
EBC. The findings of this important study demonstrate that 
letrozole is significantly more effective than tamoxifen in 
reducing recurrences, particularly in its pronounced impact 
on reducing the risk of DM that occur early (at 2 years),19 
when recurrence risk is greatest.21 With longer follow-up, 
the OS benefit is emerging in BIG 1-98 (Table 1), and these 
findings further illustrate the importance of reducing early 
DM in improving survival for women with EBC.
The MA.17 trial also has provided valuable data on the 
safety profile of letrozole in relation to placebo, whereas 
BIG 1-98 and other large AI trials such as ATAC and IES 
have compared AI therapy with tamoxifen, which confounds 
the safety interpretation. The results of MA.17 suggest no 
adverse impact of letrozole therapy on hypercholesterolemia, 
or on the overall incidence of cardiovascular AEs compared 
with placebo, whereas the AE profile of letrozole in BIG 
1-98, while similar to that of other AIs, may be subject 
to considerable “noise” by virtue of the comparison with 
tamoxifen. Nevertheless, long-term follow-up of BIG 1-98 
does not suggest an increasing risk of these important AEs 
over time. In fact, as noted earlier, the overall difference 
between treatment groups in hypercholesterolemia and 
grade 3 to 5 cardiac AEs appears to diminish. In addi-
tion, although a detailed analysis of safety is pending, the 
long-term results of the monotherapy cohort show 40 fewer 
overall (cancer-related) deaths with letrozole, an identical 
incidence of noncancer-related deaths, and safety results that 
are consistent with the known AE profile of both agents.5 
Also of considerable interest are the recent findings of the 
Z-FAST and ZO-FAST studies, which suggest not only 
that bisphosphonate therapy with ZA has a beneficial effect 
in preventing AIBL but also that such therapy may reduce 
recurrences (an unexpected outcome).46 Long-term findings 
of BIG 1-98 and MA.17 thus support the efficacy of adjuvant 
hormonal therapy with letrozole in PMW, with or without 
prior tamoxifen treatment, with a predictable and manageable 
toxicity profile expected for most patients.
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